BE1002256A3 - Medicaments. - Google Patents

Medicaments. Download PDF

Info

Publication number
BE1002256A3
BE1002256A3 BE8900222A BE8900222A BE1002256A3 BE 1002256 A3 BE1002256 A3 BE 1002256A3 BE 8900222 A BE8900222 A BE 8900222A BE 8900222 A BE8900222 A BE 8900222A BE 1002256 A3 BE1002256 A3 BE 1002256A3
Authority
BE
Belgium
Prior art keywords
drugs
sufotidine
administration
human
useful
Prior art date
Application number
BE8900222A
Other languages
English (en)
Inventor
Roger Stables
Keith Thomas Bunce
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of BE1002256A3 publication Critical patent/BE1002256A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne la co-administration en médecine humaine ou vétérinaire d'un médicament anti-inflammatoire non-stéroïdique général et de sufotidine ou de l'un de ses sels physiologiquement acceptables. Les deux ingrédients actifs, qui peuvent être administrés séparément ou peuvent être combinés en une seule préparation, sont utiles dans le traitement des états inflammatoires.
BE8900222A 1988-03-04 1989-03-03 Medicaments. BE1002256A3 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888805268A GB8805268D0 (en) 1988-03-04 1988-03-04 Medicaments

Publications (1)

Publication Number Publication Date
BE1002256A3 true BE1002256A3 (fr) 1990-11-06

Family

ID=10632893

Family Applications (1)

Application Number Title Priority Date Filing Date
BE8900222A BE1002256A3 (fr) 1988-03-04 1989-03-03 Medicaments.

Country Status (12)

Country Link
JP (1) JP2834175B2 (fr)
KR (1) KR890014110A (fr)
AU (1) AU3098489A (fr)
BE (1) BE1002256A3 (fr)
DE (1) DE3906884A1 (fr)
DK (1) DK104489A (fr)
FR (1) FR2627985A1 (fr)
GB (2) GB8805268D0 (fr)
IT (1) IT8947714A0 (fr)
NL (1) NL8900525A (fr)
SE (1) SE8900752L (fr)
ZA (1) ZA891640B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO300260B1 (no) 1993-05-05 1997-05-05 Torgersen Hans & Soenn Bilbarnestol
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
DE60006262T2 (de) * 1999-09-24 2004-05-13 Alcon, Inc. Topische suspensionsformulierungen enthaltend ciprofloxacin und dexamethason
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
KR20110079641A (ko) 2008-09-09 2011-07-07 아스트라제네카 아베 제약 조성물을 이를 필요로 하는 환자에게 전달하는 방법
MX2011013467A (es) 2009-06-25 2012-02-13 Astrazeneca Ab Metodo para tratar un paciente que corre el riesgo de desarollar una ulcera asociada a antiinflamatorio no esteroide (aine).
US9539214B2 (en) 2011-12-28 2017-01-10 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2075007A (en) * 1980-02-28 1981-11-11 Glaxo Group Ltd Heterocyclic derivatives
FR2512343A1 (fr) * 1981-09-04 1983-03-11 Glaxo Group Ltd Composition pharmaceutique contenant un medicament anti-inflammatoire systemique non steroidique et du 1-methyl-5- ( (3-( 3-1-piperidinylmethyl)phenoxy)propyl)amino)-1h-1,2,4-triazole-3-methanol ou un sel de ce compose acceptable pour l'usage pharmaceutique et procede de preparation de cette composition
GB2105193A (en) * 1981-09-04 1983-03-23 Glaxo Group Ltd Pharmaceutical compositions containing non-steroidal anti-inflammatory agents
WO1988008302A1 (fr) * 1987-04-24 1988-11-03 Abraham Sunshine Melanges contre la toux/le rhume comprenant des remedes d'antihistamine non sedative

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2075007A (en) * 1980-02-28 1981-11-11 Glaxo Group Ltd Heterocyclic derivatives
FR2512343A1 (fr) * 1981-09-04 1983-03-11 Glaxo Group Ltd Composition pharmaceutique contenant un medicament anti-inflammatoire systemique non steroidique et du 1-methyl-5- ( (3-( 3-1-piperidinylmethyl)phenoxy)propyl)amino)-1h-1,2,4-triazole-3-methanol ou un sel de ce compose acceptable pour l'usage pharmaceutique et procede de preparation de cette composition
GB2105193A (en) * 1981-09-04 1983-03-23 Glaxo Group Ltd Pharmaceutical compositions containing non-steroidal anti-inflammatory agents
WO1988008302A1 (fr) * 1987-04-24 1988-11-03 Abraham Sunshine Melanges contre la toux/le rhume comprenant des remedes d'antihistamine non sedative

Also Published As

Publication number Publication date
SE8900752D0 (sv) 1989-03-03
JPH01316319A (ja) 1989-12-21
DE3906884A1 (de) 1989-09-14
JP2834175B2 (ja) 1998-12-09
GB2216413A (en) 1989-10-11
GB8805268D0 (en) 1988-04-07
AU3098489A (en) 1989-09-07
DK104489A (da) 1989-09-05
DK104489D0 (da) 1989-03-03
SE8900752L (sv) 1989-09-05
NL8900525A (nl) 1989-10-02
GB8904879D0 (en) 1989-04-12
ZA891640B (en) 1990-03-28
FR2627985A1 (fr) 1989-09-08
IT8947714A0 (it) 1989-03-03
KR890014110A (ko) 1989-10-21

Similar Documents

Publication Publication Date Title
Johnson et al. Diagnosis and treatment of acute urinary tract infections
RU95107881A (ru) Фармацевтическая композиция для лечения аллергических заболеваний, способ антигистаминного лечения, применение композиции для получения лекарственного препарата
BR0009016A (pt) Composição de apomorfina e sildenafil
TR200000369T2 (tr) Romatizmal hastalıkların tedavisinde kullanılmak üzere kombine farmasötik preparatların üretilmesi.
KR970061244A (ko) 치매 치료용 약학 조성물
DE69819351D1 (de) Aus mehreren einzeleinheiten zusammengesetzte arzneimittel mit nicht-steroidalen wirkstoffen (nsaids)
DE3669106D1 (de) Pharmazeutische zusammensetzungen mit gehalt an flavanolignanen und phospholipiden als wirkstoffe.
ES2139842T3 (es) Uso de la melatonina para tratar a pacientes que sufren drogodependencia.
PT1027053E (pt) Metodo de prevencao de nefrotoxicidade provocada por ciclosporinas e tacrolimus
BE1002255A5 (fr) Medicaments.
BE1002295A5 (fr) Medicaments.
BE1002182A5 (fr) Compositions pharmaceutiques.
AR002727A1 (es) El uso de ridogrel para la fabricacion de un medicamento util para el tratamiento de enfermedades digestivas inflamatorias, una composicionfarmaceutica que comprende ridogrel y un procedimiento para preparar dicha composicion.
Cooper et al. The analgesic efficacy of flurbiprofen compared to acetaminophen with codeine
JP2752250B2 (ja) 鎮痛及び抗炎症作用を有する基礎治療剤
ATE91890T1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
HUP9901935A2 (hu) Gyógyszerek és terápiás szerek és más glikozaminoglikánok (GAG) dózisainak célbajuttatására alkalmas dóziskészlet
Jose et al. Levamisole in patients with recurrent herpes infection
Chapron et al. Unmasking the significant enzyme-inducing effects of phenytoin on serum carbamazepine concentrations during phenytoin withdrawal
KR890007728A (ko) 진통제 제조방법
KR910007528A (ko) 벤조디아제핀 및 페닐피릴케톤 유도체의 용도
Mahmood A double‐blind trial of a phenothiazine compound in the treatment of clinical crisis of sickle cell anaemia
Lehmann A new preparation for sedation in organic brain disease and senile disturbances.
Huskisson et al. Floctafenine: a new analgesic for use in rheumatic diseases
EP0182772A3 (fr) Compositions pharmaceutiques à libération prolongée, leur procédé de préparation et leur utilisation

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: GLAXO GROUP LTD

Effective date: 19910331